# ADC Therapeutics

Source: https://onco.cc/companies/adc-therapeutics/  
OnCo record `adc-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ADC Therapeutics, based in Lausanne, developed Zynlonta (loncastuximab tesirine), an antibody-drug conjugate built on its pyrrolobenzodiazepine payload platform and approved in diffuse large B-cell lymphoma. It is now switching to exatecan-based payloads, so its future rests on changing platform while staying independent.

## Summary

ADC Therapeutics, based in Lausanne and listed as ADCT, developed Zynlonta, or loncastuximab tesirine, and the pyrrolobenzodiazepine payload platform behind it. Loncastuximab is approved in diffuse large B-cell lymphoma, the LOTIS-5 and LOTIS-7 trials test it in combinations, and the company is moving to exatecan-based next-generation ADCs. OnCo links it to diffuse large B-cell lymphoma and to the loncastuximab tesirine drug record. Whether a company built on one payload can change platform and stay independent is the open question. Loncastuximab tesirine has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: ADC Therapeutics S.A.; ADC Therapeutics SA
- HQ: Lausanne
- Type: biotech
- Website: https://adctherapeutics.com
- Ticker: ADCT

## Sources

- Official website: https://adctherapeutics.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- drugs: [Loncastuximab tesirine](https://onco.cc/drugs/zynlonta/)
- trials: [Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym](https://onco.cc/trials/nct04384484/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- companies: [Sobi (Swedish Orphan Biovitrum)](https://onco.cc/companies/sobi/)

---
JSON: https://onco.cc/api/v1/entities/adc-therapeutics.json